Antithymocyte immunoglobulin (rabbit)
- Generic Name
- Antithymocyte immunoglobulin (rabbit)
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-60-9
- Unique Ingredient Identifier
- D7RD81HE4W
- Background
Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of T-cells.
- Indication
For prevention of renal transplant rejection
- Associated Conditions
- Rejection Acute Renal
- Associated Therapies
- -
A Dose Escalation Study in de Novo Renal Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- ITB-Med LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04311632
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Kansas University Medical Center, Kansas City, Kansas, United States
rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)
- Conditions
- Interventions
- First Posted Date
- 2020-03-10
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Institute for Clinical and Experimental Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT04302805
- Locations
- 🇨🇿
Institute for Clinical and Experimental Medicine, Prague, Czechia
Stem Cell Transplantation in Crohn's Disease
- Conditions
- Interventions
- Drug: MesnaDrug: CyclophosphamideDrug: FilgrastimProcedure: Apheresis catheter placementProcedure: LeukapheresisDrug: FludarabineDrug: MethylprednisoloneDrug: DiphenhydramineDrug: AcetaminophenDrug: anti-thymocyte globulin (rabbit)Drug: lymphocyte immune globulinBiological: Peripheral Blood Stem Cell InfusionDrug: Cytoxan
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT04224558
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- McMaster University
- Target Recruit Count
- 80
- Registration Number
- NCT04202835
- Locations
- 🇨🇦
Hôpital de l'Enfant-Jésus, Québec City, Quebec, Canada
🇦🇺Kinghorn Cancer Centre, St Vincent's Health Network, Darlinghurst, New South Wales, Australia
🇦🇺Royal North Shore Hospital, St. Leonards, New South Wales, Australia
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 266
- Registration Number
- NCT04203108
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Tacrolimus After rATG and Infliximab Induction Immunosuppression (RIMINI)
- Conditions
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Prof. Dr. Petra Reinke
- Target Recruit Count
- 68
- Registration Number
- NCT04114188
- Locations
- 🇩🇪
Charité University Medicine Berlin, Berlin, Germany
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases
- Conditions
- Interventions
- Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10Drug: FludarabineDrug: CyclophosphamideBiological: Lapine T-Lymphocyte Immune GlobulinRadiation: Total-Body IrradiationProcedure: Hematopoietic Cell TransplantationDrug: Mycophenolate MofetilDrug: SirolimusProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04083183
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Viela Bio (acquired by Horizon Therapeutics)
- Target Recruit Count
- 25
- Registration Number
- NCT04046549
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸Duke University School of Medicine, Durham, North Carolina, United States
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 823
- Registration Number
- NCT04009525
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
- Conditions
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 114
- Registration Number
- NCT03852407
- Locations
- 🇧🇪
CHU UCL Namur Godinne, Yvoir, Belgium
🇧🇪UZ Gent, Gent, Belgium
🇧🇪UCL St Luc, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.